September 20, 2022

 

Boehringer Ingelheim launches Fencovis® vaccine to prevent calf diarrhea

 
 

 

Boehringer Ingelheim is adding a new vaccine to its bovine vaccine portfolio with the launch of Fencovis® for the prevention of calf diarrhea and providing passive immunity to calves through the cows' maternal colostrum.

 

Calf diarrhea, also known as calf scour, is a sign of a range of gastrointestinal diseases affecting unweaned newborn calves. It is multifactorial in nature involving infectious and non-infectious causes. The immature immune system of the neonatal calf that is unable to produce its own antibodies makes calf scour even more challenging to get under control.

 

A 2021 German study reported the incidence of diarrhea to be 18.5% and the most common disease observed in almost 14,000 neonatal calves examined on 731 German dairy herds.

 

With Fencovis®, Boehringer Ingelheim now launches the first vaccine licensed for prevention of calf scour at the World Buiatrics Congress in Madrid, Spain, a key event in the cattle industry.

 

Fencovis® is indicated for the active immunisation of pregnant heifers and cows to stimulate the development of antibodies against rotavirus, coronavirus and E. coli F5 (K99) adhesin, resulting in the passive immunisation of calves against neonatal diarrhea. In calves fed with colostrum and milk from vaccinated cows, these antibodies have been demonstrated to prevent diarrhea caused by rotavirus and E. coli F5 (K99) adhesin and reduce the incidence and severity of diarrhea caused by coronavirus. Viral shedding in calves infected by rotavirus and coronavirus was also reduced by Fencovis®.

 

Together with Fencovis®, Boehringer Ingelheim provides a holistic lean approach to cattle farming through its training and support services. This is aimed at vets to allow them to further improve calf management and ensure optimal gut and immune health, inspiring excellence in calf rearing.

 

Gerald Behrens, global head of ruminants at Boehringer Ingelheim, said: "We are excited to launch the first vaccine in the market that prevents calf scour. Fencovis®, together with our lean management trainings for vets, supports excellence in calf management, particularly around the vital feeding of colostrum to calves. Boehringer Ingelheim will provide guidance to veterinarians for the use of lean management tools to maximise the impact of Fencovis® on farm and help farmers produce healthier and more productive calves."

 

Following the latest registration studies, Fencovis®, which is a suspension for injection, has been shown to provide unparalleled protection using a non-oil adjuvant. Boehringer Ingelheim’s new vaccine comes with flexible presentations including a single dose pack.

 

Fencovis® will become available in certain markets within the European Union and in the United Kingdom.

 

- Boehringer Ingelheim

Video >

Follow Us

FacebookTwitterLinkedIn